Enhancing the HSV-1-mediated antitumor immune response by suppressing Bach1

Author(s):  
Chaohu Pan ◽  
Qiaomei Cai ◽  
Xiaorong Li ◽  
Lili Li ◽  
Liping Yang ◽  
...  
Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3386
Author(s):  
Bart Spiesschaert ◽  
Katharina Angerer ◽  
John Park ◽  
Guido Wollmann

The focus of treating cancer with oncolytic viruses (OVs) has increasingly shifted towards achieving efficacy through the induction and augmentation of an antitumor immune response. However, innate antiviral responses can limit the activity of many OVs within the tumor and several immunosuppressive factors can hamper any subsequent antitumor immune responses. In recent decades, numerous small molecule compounds that either inhibit the immunosuppressive features of tumor cells or antagonize antiviral immunity have been developed and tested for. Here we comprehensively review small molecule compounds that can achieve therapeutic synergy with OVs. We also elaborate on the mechanisms by which these treatments elicit anti-tumor effects as monotherapies and how these complement OV treatment.


Pathobiology ◽  
2021 ◽  
pp. 1-17
Author(s):  
Ana Margarida Barbosa ◽  
Alexandra Gomes-Gonçalves ◽  
António G. Castro ◽  
Egídio Torrado

The immune system plays a critical role in preventing cancer development and progression. However, the complex network of cells and soluble factor that form the tumor microenvironment (TME) can dictate the differentiation of tumor-infiltrating leukocytes and shift the antitumor immune response into promoting tumor growth. With the advent of cancer immunotherapy, there has been a reinvigorated interest in defining how the TME shapes the antitumor immune response. This interest brought to light the microbiome as a novel player in shaping cancer immunosurveillance. Indeed, accumulating evidence now suggests that the microbiome may confer susceptibility or resistance to certain cancers and may influence response to therapeutics, particularly immune checkpoint inhibitors. As we move forward into the age of precision medicine, it is vital that we define the factors that influence the interplay between the triad immune system-microbiota-cancer. This knowledge will contribute to improve the therapeutic response to current approaches and will unravel novel targets for immunotherapy.


HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S262
Author(s):  
R. Martins ◽  
C. Martín-Sierra ◽  
P. Laranjeira ◽  
A.M. Abrantes ◽  
J.G. Tralhão ◽  
...  

1992 ◽  
Vol 11 (2) ◽  
pp. 137
Author(s):  
Drew Pardoll ◽  
Paul Golumbek ◽  
Liz Jaffee ◽  
Hy Levitsky ◽  
Glen Dranoff ◽  
...  

2008 ◽  
Vol 53 (1) ◽  
pp. 73-83 ◽  
Author(s):  
V. Ďurmanová ◽  
M. Sapák ◽  
J. Košovský ◽  
I. Režuchová ◽  
M. Kúdelová ◽  
...  

2021 ◽  
Author(s):  
Mathieu Rouanne ◽  
Julien Adam ◽  
Camélia Radulescu ◽  
Séverine Mouraud ◽  
Delphine Bredel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document